SCHEMBL21355973

SCHEMBL21355973

CC1(C)O[C@H]2[C@@H](O1)[C@H](n1ccc3c(N)ncnc31)O[C@@H]2[C@@H]1OCc2ccc(Cl)cc21

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 20/20 0.74
▸ WDR77 Q9BQA1 20/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384103 1.00 PRMT5 (0.74) PRMT5WDR77
SCHEMBL29383271 0.93 PRMT5 (0.74) PRMT5WDR77
SCHEMBL29383028 0.93 PRMT5 (0.74) PRMT5WDR77
SCHEMBL21356293 0.93 PRMT5 (0.74) PRMT5WDR77
SCHEMBL21356084 0.93 PRMT5 (0.74) PRMT5WDR77
SCHEMBL24489732 0.93 PRMT5 (0.74) PRMT5WDR77
SCHEMBL21355965 0.91 PRMT5 (0.63) PRMT5WDR77
SCHEMBL29383345 0.91 PRMT5 (0.63) PRMT5WDR77
SCHEMBL21356339 0.90 PRMT5 (0.75) PRMT5WDR77
SCHEMBL29380881 0.90 PRMT5 (0.75) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459950-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2025-11-04 — — US disclosed
US-12440506-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2025-10-14 — — US disclosed
EP-3765461-B1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INC (US) 2023-08-30 — — EP disclosed
US-20220177481-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2022-06-09 — — US disclosed
US-20220177481-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2022-06-09 — — US disclosed
US-20220152073-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2022-05-19 — — US disclosed
US-20220152073-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2022-05-19 — — US disclosed
US-11254683-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-02-22 — — US disclosed
US-11254683-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-02-22 — — US disclosed
EP-3946352-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 Prelude Therapeutics, Incorporated (US) 2022-02-09 — — EP disclosed
US-20200361945-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2020-11-19 — — US disclosed
WO-2020206299-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-10-08 — — WO disclosed
WO-2020206299-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-10-08 — — WO disclosed
US-20200291037-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INC (US) 2020-09-17 — — US disclosed
US-20200291037-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INC (US) 2020-09-17 — — US disclosed
US-10711007-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2020-07-14 — — US disclosed
US-10711007-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2020-07-14 — — US disclosed
US-20190284193-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2019-09-19 — — US disclosed
US-20190284193-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2019-09-19 — — US disclosed
WO-2019178368-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2019-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459950-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-10711007-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-11254683-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-20200361945-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-20220152073-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 57/4885
US-12440506-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 57/4885
US-20190284193-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-20220177481-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-20200291037-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback